JMDC Inc.

DB:6JM Stock Report

Market Cap: €1.7b

JMDC Valuation

Is 6JM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6JM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6JM (€24.8) is trading above our estimate of fair value (€14.64)

Significantly Below Fair Value: 6JM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6JM?

Key metric: As 6JM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6JM. This is calculated by dividing 6JM's market cap by their current earnings.
What is 6JM's PE Ratio?
PE Ratio67.1x
EarningsJP¥4.13b
Market CapJP¥277.47b

Price to Earnings Ratio vs Peers

How does 6JM's PE Ratio compare to its peers?

The above table shows the PE ratio for 6JM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.5x
NXU Nexus
44.1x17.1%€1.2b
COP CompuGroup Medical SE KGaA
29x32.9%€730.5m
M3V MeVis Medical Solutions
8xn/a€45.1m
AJ91 DocCheck
17xn/a€41.4m
6JM JMDC
67.1x24.9%€277.5b

Price-To-Earnings vs Peers: 6JM is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the peer average (24.5x).

Price to Earnings Ratio vs Industry

How does 6JM's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
6JM 67.1xIndustry Avg. 17.9xNo. of Companies4PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 6JM is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the European Healthcare Services industry average (17.8x).

Price to Earnings Ratio vs Fair Ratio

What is 6JM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6JM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio67.1x
Fair PE Ratio29.3x

Price-To-Earnings vs Fair Ratio: 6JM is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the estimated Fair Price-To-Earnings Ratio (29.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6JM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€24.80
€33.83
+36.4%
17.6%€42.71€23.80n/a11
Nov ’25€24.20
€34.63
+43.1%
18.9%€44.28€24.67n/a11
Oct ’25€28.60
€34.63
+21.1%
18.9%€44.28€24.67n/a11
Sep ’25€26.00
€32.41
+24.7%
22.1%€43.32€22.28n/a11
Aug ’25€18.80
€28.27
+50.4%
27.9%€40.86€19.44n/a10
Jul ’25€17.40
€28.24
+62.3%
30.4%€41.02€19.51n/a9
Jun ’25€15.70
€28.93
+84.3%
29.0%€41.01€19.51n/a10
May ’25€18.70
€32.81
+75.5%
22.0%€42.53€22.18n/a10
Apr ’25€21.80
€36.19
+66.0%
25.0%€56.39€22.62n/a10
Mar ’25€23.00
€36.76
+59.8%
25.0%€56.56€22.69n/a10
Feb ’25€23.60
€39.10
+65.7%
24.8%€63.39€28.35n/a10
Jan ’25€26.60
€40.41
+51.9%
23.6%€64.87€30.12n/a10
Dec ’24€25.80
€39.27
+52.2%
23.3%€61.77€28.68n/a10
Nov ’24€26.60
€41.60
+56.4%
24.7%€66.35€30.39€24.2010
Oct ’24€33.60
€43.10
+28.3%
25.1%€66.38€30.41€28.608
Sep ’24€27.00
€42.41
+57.1%
26.7%€66.14€30.30€26.009
Aug ’24€33.60
€45.32
+34.9%
21.1%€66.29€33.78€18.809
Jul ’24n/a
€44.67
0%
22.3%€66.06€33.66€17.409
Jun ’24€36.60
€45.35
+23.9%
22.0%€64.03€34.01€15.709
May ’24€31.60
€47.07
+48.9%
24.5%€66.00€32.65€18.708
Apr ’24€30.40
€47.31
+55.6%
26.3%€66.65€32.98€21.807
Mar ’24€28.40
€47.50
+67.2%
26.8%€67.23€33.26€23.007
Feb ’24€29.60
€47.78
+61.4%
26.8%€67.17€30.40€23.607
Jan ’24€26.20
€50.48
+92.7%
25.5%€70.88€35.09€26.607
Dec ’23€35.60
€52.40
+47.2%
23.5%€68.05€36.75€25.806
Nov ’23€34.46
€53.02
+53.9%
24.6%€71.91€37.31€26.606

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

4A5

€18.18

7D

-2.7%

1Y

6.1%

Shandong Weigao Group Medical Polymer

HK$20.7b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.54

7D

-1.8%

1Y

-37.1%

LNA Santé

€242.3m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-6.8%

1Y

15.7%